- Home
- GRNT vs RLMD Comparison
GRNT vs RLMD Comparison
Compare GRNT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRNT | RLMD |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.8M | 777.2M |
| IPO Year | 2022 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GRNT | RLMD |
|---|---|---|
| Price | $5.00 | $7.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $12.40 |
| AVG Volume (30 Days) | 740.8K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.36% | N/A |
| EPS Growth | 28.57 | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $450,306,000.00 | $13,070.00 |
| Revenue This Year | $18.12 | N/A |
| Revenue Next Year | $13.12 | N/A |
| P/E Ratio | $30.97 | ★ N/A |
| Revenue Growth | 18.49 | ★ 154.83 |
| 52 Week Low | $4.18 | $0.44 |
| 52 Week High | $6.59 | $8.00 |
Technical Indicators
Market Signals| Indicator | GRNT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.80 | 53.97 |
| Support Level | $4.84 | $6.81 |
| Resistance Level | $5.45 | $7.41 |
| Average True Range (ATR) | 0.22 | 0.44 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 10.14 | 45.02 |
Price Performance
Historical ComparisonAbout GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.